Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics

Blood (2024) 143 (13): 1242–1258.

https://doi.org/10.1182/blood.2023021581

Published: 2024

Includes: Supplemental data

Journal Articles

TP53 CRISPR/Cas9 Reveals Strict BAX Dependence in the Response to BH3 Mimetic Targeting MCL1

Romane Durand, Domitille Costes-Tertrais, Geraldine Descamps, Christelle Dousset, Sophie Maïga, Jean-Baptiste Alberge, Elise Douillard, Jennifer Derrien, Celine Bellanger, David Chiron, Stephane Minvielle, Cyrille Touzeau, Philippe Moreau, Martine Amiot, Patricia Gomez-Bougie, Agnes Moreau-Aubry, Catherine Pellat-Deceunynck

Blood (2022) 140 (Supplement 1): 4198–4199.

https://doi.org/10.1182/blood-2022-155862

Published: 2022

Journal Articles

STP938, a Selective CTPS1 Inhibitor, Shows Single Agent Activity and Synergy with BCL2 Inhibition in Preclinical Models of Mantle Cell Lymphoma

David Chiron, Emmanuelle Menoret, Charlotte Kervoelen, Sophie Maïga, Celine Bellanger, Benoit Tessoulin, Cyrille Touzeau, Hélène Asnagli, Andy Parker, Philip Beer, Catherine Pellat-Deceunynck

Blood (2022) 140 (Supplement 1): 6014–6015.

https://doi.org/10.1182/blood-2022-159449

Published: 2022

Journal Articles

BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment

Patricia Gomez-Bougie, Sophie Maiga, Benoît Tessoulin, Jessie Bourcier, Antoine Bonnet, Manuel S. Rodriguez, Steven Le Gouill, Cyrille Touzeau, Philippe Moreau, Catherine Pellat-Deceunynck, Martine Amiot

Blood (2018) 132 (25): 2656–2669.

https://doi.org/10.1182/blood-2018-03-836718

Published: 2018

Includes: Supplemental data

Journal Articles

Respective Place of Venetoclax and MCL1 BH3 Mimetics in Multiple Myeloma Treatment

Patricia Gomez-Bougie, PhD, Sophie Maïga, Benoit Tessoulin, MD, Jessie Bourcier, MD, Antoine Bonnet, MD, Géraldine Descamps, PhD, Carolane Seiller, Cyrille Touzeau, MD PhD, Philippe Moreau, Catherine Pellat-Deceunynck, PhD, Martine Amiot, PhD

Blood (2018) 132 (Supplement 1): 953.

https://doi.org/10.1182/blood-2018-99-109987

Published: 2018

Journal Articles

The Use of a BH3 Mimetic Toolkit Reveals a Switch of Myeloma Patients Dependency from BCL2 at Diagnosis to MCL1 at Relapse

Antoine Bonnet, MD, Jessie Bourcier, MD, Patricia Gomez-Bougie, PhD, Sophie Maïga, Benoit Tessoulin, MD, Philippe Moreau, MDPhD, Steven Le Gouill, MDPhD, Catherine Pellat-Deceunynck, PhD, Cyrille Touzeau, MD PhD, Martine Amiot, PhD

Blood (2017) 130 (Supplement 1): 4383.

https://doi.org/10.1182/blood.V130.Suppl_1.4383.4383

Published: 2017

Journal Articles

Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma

David Chiron, Céline Bellanger, Antonin Papin, Benoit Tessoulin, Christelle Dousset, Sophie Maiga, Anne Moreau, Julie Esbelin, Valérie Trichet, Selina Chen-Kiang, Philippe Moreau, Cyrille Touzeau, Steven Le Gouill, Martine Amiot, Catherine Pellat-Deceunynck

Blood (2016) 128 (24): 2808–2818.

https://doi.org/10.1182/blood-2016-06-720490

Published: 2016

Includes: Supplemental data

Journal Articles

Lymphoid-like Environment, Which Promotes Proliferation and Induces Resistance to BH3-Mimetics, Is Counteracted By Obinutuzumab in MCL: Biological Rationale for the Oasis Clinical Trial

David Chiron, PhD, Celine Bellanger, Antonin Papin, Benoit Tessoulin, MD, Christelle Dousset, Sophie Maiga, Anne Moreau, MD, Julie Esbelin, MD, Valerie Trichet, PhD, Selina Chen-Kiang, PhD, Philippe Moreau, Cyrille Touzeau, MD, Steven Le Gouill, MD PhD, Martine Amiot, Catherine Pellat-Deceunynck, PhD

Blood (2016) 128 (22): 1096.

https://doi.org/10.1182/blood.V128.22.1096.1096

Published: 2016

Journal Articles

Hypoxia-Inducible Factor (HIF)-1alpha Inhibitionin Myeloma Cells Significantly Increases the Anti-Myeloma Effect of Lenalidomide in Vivo

Paola Storti, PhD, Valentina Marchica, Denise Toscani, PhD, Irma Airoldi, PhD, Sophie Maiga, PhD, Marina Bolzoni, PhD, Nicoletta Campanini, Eugenia Martella, MD, Cristina Mancini, MD, Valentina Ferri, Gaetano Donofrio, PhD, Martine Amiot, PhD, Franco Aversa, MD, Nicola Giuliani, MD PhD

Blood (2015) 126 (23): 3012.

https://doi.org/10.1182/blood.V126.23.3012.3012

Published: 2015

Journal Articles

PRIMA-1 Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance

Benoît Tessoulin, Géraldine Descamps, Philippe Moreau, Sophie Maïga, Laurence Lodé, Catherine Godon, Séverine Marionneau-Lambot, Thibauld Oullier, Steven Le Gouill, Martine Amiot, Catherine Pellat-Deceunynck

Blood (2014) 124 (10): 1626–1636.

https://doi.org/10.1182/blood-2014-01-548800

Published: 2014

Journal Articles

Vitamin D3 and Lenalidomide Synergize To Induce Apoptosis In Mantle Cell Lymphoma Via Demethylation Of BIK

Carole Brosseau, PhD, Christelle Dousset, Cyrille Touzeau, MD, Sophie Maiga, Philippe Moreau, MD, Martine Amiot, PhD, Steven Le Gouill, MD, PhD, Catherine Pellat-Deceunynck, PhD

Blood (2013) 122 (21): 1830.

https://doi.org/10.1182/blood.V122.21.1830.1830

Published: 2013

Journal Articles

Cereblon (CRBN) Splicing Could Influence Response To IMiDs : A New PCR Strategy to Easily Detect and Semi-Quantify Loss Of The IMiDs Binding Domain

Blood (2013) 122 (21): 3107.

https://doi.org/10.1182/blood.V122.21.3107.3107

Published: 2013

Journal Articles

Combination Of 2-Deoxy-D-Glucose With ABT-199 Efficiently Kills All Molecular Subgroups Of Myeloma Cells

Maxime Halliez, Sophie Maïga, Cyrille Touzeau, MD, Patricia Gomez-Bougie, PhD, Steven Le Gouill, MD, PhD, Marie-Christine Bene, PharmSciD, PhD, Philippe Moreau, MD, Catherine Pellat-Deceunynck, PhD, Martine Amiot, PhD

Blood (2013) 122 (21): 1921.

https://doi.org/10.1182/blood.V122.21.1921.1921

Published: 2013

Journal Articles

TP53 Is Not Involved in the Apoptosis Induced by RITA

Sylvanie Surget, PhD, in, training, Vincent Normant, Carole Brosseau, PhD, Sophie Maiga, Patricia Gomez-Bougie, Géraldine Descamps, Steven Le Gouill, MD, PhD, Martine Amiot, Catherine Pellat-Deceunynck, PhD

Blood (2011) 118 (21): 1848.

https://doi.org/10.1182/blood.V118.21.1848.1848

Published: 2011

Journal Articles

ABT-737 is highly effective against molecular subgroups of multiple myeloma

Linda Bodet, Patricia Gomez-Bougie, Cyrille Touzeau, Christelle Dousset, Géraldine Descamps, Sophie Maïga, Hervé Avet-Loiseau, Régis Bataille, Philippe Moreau, Steven Le Gouill, Catherine Pellat-Deceunynck, Martine Amiot

Blood (2011) 118 (14): 3901–3910.

https://doi.org/10.1182/blood-2010-11-317438

Published: 2011

Includes: Supplemental data

Journal Articles

Myeloma Cell Self-Renewal Depends on JAG2 Expression and Is Mediated by IGF1 or SCF Loop

David Chiron, PhD, in, training, Sophie Maiga, Géraldine Descamps, Severine Marionneau, Thilbaud Ouiller, Jerome Moreaux, Bernard Klein, PhD, MD, Philippe Moreau, Jean-Luc Harousseau, Regis Bataille, MD, PhD, Martine Amiot, Catherine Pellat-Deceunynck, PhD

Blood (2010) 116 (21): 127.

https://doi.org/10.1182/blood.V116.21.127.127

Published: 2010

Journal Articles

Weak Sensitivity of Myeloma Cells to CD38 or CD138-ADCC

Beatrice Clemenceau, PhD, Regine Vivien, Géraldine Descamps, Sophie Maiga, Martine Amiot, Henri Vié, Catherine Pellat-Deceunynck, PhD

Blood (2010) 116 (21): 4072.

https://doi.org/10.1182/blood.V116.21.4072.4072

Published: 2010

Journal Articles

Unsupervised Analysis of Gene Expression Profile of 37 Human Myeloma Cell Lines Identifies 5 Classes of HMCL Characterized by a Set of 213 Genes Related to Molecular Classification of Patients with Multiple Myeloma

Jerome Moreaux, Bernard Klein, Thierry Reme, Michel Jourdan, Sophie Maiga, Régis Bataille, Martine Amiot, Catherine Pellat-Deceunynck

Blood (2008) 112 (11): 2702.

https://doi.org/10.1182/blood.V112.11.2702.2702

Published: 2008

NARROW

A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics

TP53 CRISPR/Cas9 Reveals Strict BAX Dependence in the Response to BH3 Mimetic Targeting MCL1

STP938, a Selective CTPS1 Inhibitor, Shows Single Agent Activity and Synergy with BCL2 Inhibition in Preclinical Models of Mantle Cell Lymphoma

BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment

Respective Place of Venetoclax and MCL1 BH3 Mimetics in Multiple Myeloma Treatment

The Use of a BH3 Mimetic Toolkit Reveals a Switch of Myeloma Patients Dependency from BCL2 at Diagnosis to MCL1 at Relapse

Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma

Lymphoid-like Environment, Which Promotes Proliferation and Induces Resistance to BH3-Mimetics, Is Counteracted By Obinutuzumab in MCL: Biological Rationale for the Oasis Clinical Trial

Hypoxia-Inducible Factor (HIF)-1alpha Inhibitionin Myeloma Cells Significantly Increases the Anti-Myeloma Effect of Lenalidomide in Vivo

PRIMA-1 Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance

Vitamin D3 and Lenalidomide Synergize To Induce Apoptosis In Mantle Cell Lymphoma Via Demethylation Of BIK

Cereblon (CRBN) Splicing Could Influence Response To IMiDs : A New PCR Strategy to Easily Detect and Semi-Quantify Loss Of The IMiDs Binding Domain

Combination Of 2-Deoxy-D-Glucose With ABT-199 Efficiently Kills All Molecular Subgroups Of Myeloma Cells

TP53 Is Not Involved in the Apoptosis Induced by RITA

ABT-737 is highly effective against molecular subgroups of multiple myeloma

Myeloma Cell Self-Renewal Depends on JAG2 Expression and Is Mediated by IGF1 or SCF Loop

Weak Sensitivity of Myeloma Cells to CD38 or CD138-ADCC

Unsupervised Analysis of Gene Expression Profile of 37 Human Myeloma Cell Lines Identifies 5 Classes of HMCL Characterized by a Set of 213 Genes Related to Molecular Classification of Patients with Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only